Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intra-Cellular Therapies Inc (ICTI), a subsidiary of Johnson & Johnson, is a biopharmaceutical company that discovers, develops, and commercializes intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. The company pipeline products include lumateperone for major depressive disorder, bipolar depression and pediatric diseases. It markets its products under the brands CNSProfile and CAPLYTA. ICTI is headquartered in Bedminster, New Jersey, the US.
Headquarters
United States of America
Address
Suite 6, 135 Route 202/206, Bedminster, New Jersey, 07921
Website
www.intracellulartherapies.com
Telephone
1 888 2524824
No of Employees
860
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$680.9M
Intra-Cellular Therapies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | CNSProfile |
| Lumateperone: | CAPLYTA |
| Major Depressive Disorder-Adjunctive Therapy | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In April, the company was acquired by Johnson & Johnson, a pharma company, for US$14.6 billion. |
| 2024 | Regulatory Approval | In December, the company submitted a new drug application to the US Food and Drug Administration for CAPLYTA (lumateperone) to treat Major Depressive Disorder in adults, as adjunctive therapy to antidepressants. |
| 2021 | Regulatory Approval | In December, the company announced U.S. Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults. |
Competitor Comparison
| Key Parameters | Intra-Cellular Therapies Inc | Supernus Pharmaceuticals Inc | Axsome Therapeutics Inc | Concert Pharmaceuticals Inc | Intellect Neurosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bedminster | Rockville | New York City | Lexington | Englewood Cliffs |
| State/Province | New Jersey | Maryland | New York | Massachusetts | New Jersey |
| No. of Employees | 860 | 674 | 683 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sharon Mates, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2013 | 71 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer